

Harel Dahari

CONTACT INFORMATION

The Program for Experimental & Theoretical Modeling
 Division of Hepatology, Department of Medicine, hdahari@lumc.edu, (708) 216-4682
 Loyola University Medical Center Fax: (708) 216-6299
 2160 S. First Ave, Maywood, IL 60153

Theoretical Biology & Biophysics Group, daharih@lanl.gov, (505) 665-7743
 MS K710, T-6 Fax: (505) 665-3493
 Los Alamos National Laboratory
 Los Alamos, NM 87545

EDUCATION AND EMPLOYMENT HISTORY

Assistant Professor (tenure track), The Program for Experimental and Theoretical Modeling,
 Department of Medicine, Division of Hepatology, Loyola University Medical Center (Sep.
 2012 –)

Staff Scientist, Theoretical Biology & Biophysics, T-6, Los Alamos National Laboratory, Los
 Alamos, NM (Aug. 2010 –)

Research Associate Professor (faculty), Department of Medicine, Section of Hepatology,
 University of Illinois at Chicago (Aug. 2007 – Sep 2012)

Post-doc fellow, Theoretical Biology & Biophysics, T-10, LANL, Los Alamos, NM.
 Host: Dr. Alan S. Perelson (Oct. 2004 – July 2007).

Ph.D., Biomathematics, Bar Ilan University, Ramat Gan, Israel.
 Dissertation: Viral Dynamics of the Hepatitis C Virus
 Advisor: Prof. Avidan U. Neumann (June 2004).

Teacher's Diploma, Physics (May 2004).

M.Sc., Biomathematics, Bar Ilan University, Ramat Gan, Israel.

Thesis: Hepatitis C Viral (HCV) Dynamics In-Vivo during Anti-Viral and Immunological Therapy
 Advisor: Prof. Avidan U. Neumann (June 1999).

B.Sc., Biophysics, Bar Ilan University, Ramat Gan, Israel.
 Advisor: Prof. Elisha Haas (June 1997).

OTHER POSITIONS

Adjunct Research Associate Professor of Biology, University of New Mexico, USA 2010-
 Lecturer, Department of Medicine, University of Illinois at Chicago 2012-

RESEARCH INTERESTS

Theoretical biology with an emphasis on viral-host dynamics during infection and treatment in
 vitro and in vivo including preventive and treatment optimization.

SELECTED PUBLICATIONS

Graw F, Martin DN, Perelson AS, Uprichard SL, **Dahari H**. Quantification of HCV cell-to-cell spread
 using a stochastic modeling approach. *J. Virology* (2015); in press.

Dahari H, Shteingart S, Gafanovich I, Cotler SJ, D'Amato M, Pohl RT, Weiss G, Ashkenazi YJ,
 Tichler T, Goldin E, Lurie Y. Sustained virological response with intravenous silibinin: individualized

IFN-free therapy via real-time modeling of HCV kinetics. **Liver International** (2015); 35(2):289-294; [I.F. 4.4] NIHMSID #630488 [**Featured as Debates in Hepatology with two commentaries on our study**: Meissner EG. 35(2):295-296 ; Guedj G & Nguyen T. 35(2):297-298]

Guedj J, Rotman Y, Cotler S.J, Schmid P, Albrecht J, Haynes-Williams V, Liang T.J, Hoofnagle J.H, Heller T, **Dahari H**. Understanding early hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. **Hepatology** (2014); 60(6):1902-10 [I.F. 12.0]; NIHMSID #622381

Guedj J*, **Dahari H***, Rong L, Sansone N, Nettles RE, Cotler SJ, Layden JE, Uprichard SL, Perelson AS. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a new estimate of the hepatitis C virus half-life. **Proc Natl Acad Sci U S A**. (2013) Mar 5;110(10):3991-6 [**Impact Factor, I. F. 9.7**] (* **equal contributors**). Selected by Faculty of 1000.

Zhang J, Lipton HL, Perelson AS, **Dahari H**. Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection. **J Virology** (2013) April;87(7):4052-4059 [**I. F. 5.1**]

L. Rong, **H. Dahari**, R.M. Ribeiro, A.S. Perelson. Rapid emergence of hepatitis C virus protease inhibitor resistance. **Science Translational Medicine (AAAS)** (2010) 2, 30ra32. [**I.F., 14.4**]

Neumann AU, Lam NP, **Dahari H**, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. **Science (AAAS)** (1998) 282:103-7. [**I.F., 29.2**]

PUBLICATIONS

Canini L, DebRoy S, Mariño Z, Crespo G, Navasa M, D'Amato M, Ferenci P, Cotler SJ, Fornis X, Perelson AS, **Dahari H**. Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. **Antiviral Therapy** (2014) in press [**I.F. 4.1**] NIHMSID # 639247

Rong L, Guedj J, **Dahari H**, Perelson AS. Treatment of hepatitis C with an interferon-based lead-in phase: A perspective from mathematical modeling. **Antiviral Therapy** (2014) 19:469-477 [**I.F. 4.1**]

Rotman Y, Nouredin M, Feld JJ, Guedj J, Witthaus M, Han H, Park Y, Park SH, Heller T, Ghany MG, Doo E, Koh C, Abdalla A, Gara N, Sarkar S, Thomas E, Ahlenstiel G, Edlich B, Titerence R, Hogdal L, Rehermann B, **Dahari H**, Perelson AS, Hoofnagle JH and Liang TJ. Effect of Ribavirin on Viral Kinetics and Liver Gene Expression in Chronic Hepatitis C. **Gut** (2014) Jan;63(1):161-9 [**I.F. 10.1**]

Gutfraind A, Boodram B, Ouellet LJ, Prachand N, Perelson AS, Feinstone S, Novak RM, Mniszewski SM, Del Valle SY, **Dahari H**, Major M. Implementing a data-driven model of hepatitis C infections in metropolitan Chicago: a concept paper. Accepted at the Proceedings of the 8th INFORMS Workshop on Data Mining and Health Informatics 2013.

Rong L*, Guedj J*, **Dahari H***, Smith P, Perelson AS. Multiscale modeling approach predicts that the protease inhibitor danoprevir blocks several distinct stages of the HCV replication in vivo. **PLoS Comp Bio** (2013) Mar;9(3):e1002959 [**I. F. 5.2**] (* **equal contributors**)

Guedj J*, **Dahari H***, Pohl RT, Ferenci P, Perelson AS Understanding silibinin's modes of action against HCV using viral kinetic modeling. **J Hepatology** (2012) 56: 1019-1024 [I.F. 9.3] (* **equal contributors**)

Guedj J, **Dahari H**, Shudo E, Smith P, Perelson AS. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). **Hepatology** (2012) 55(4):1030-7 [I.F. 12.0]

Araújo ESA*, **Dahari H***, Cotler SJ, Layden TJ, Neumann AU, Melo CE, Tatsch FF, Barone AA. Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients. **J Acquir Immune Defic Syndr** (2011); 56:95-99 [**I.F. 4.6**] (* **equal contributors**)

Evaldo S.A. Araújo, **Harel Dahari**, Avidan U. Neumann, Norma de Paula Cavalheiro, Carlos Eduardo Melo, Evandro Sobroza de Melo, Thomas J. Layden, Scott J. Cotler, Antônio Alci Barone. Very early prediction of response to HCV treatment with peg-IFN- α -2a and ribavirin in HIV/HCV coinfecting patients. **J Viral Hepatitis** (2011); Apr;18(4):e52-60 [**I.F. 3.3**]

Harel Dahari, Stephen Feinstone, Marian Major. Quantitative evaluation of HCV vaccine success: a meta-analysis. **Gastroenterology** (2010); Sep 139:965-974 [**I.F. 12.6**]

Harel Dahari, Evaldo S. Affonso de Araujo, Bart L. Haagmans, Thomas J. Layden, Scott J. Cotler, Antonio A. Barone, Avidan U. Neumann. Pharmacodynamics of PEG-IFN α -2a in HIV/HCV co-infected patients: Implications for treatment outcomes. **J Hepatology** (2010); 53: 460-467 [**I.F. 9.3**]. (see Editorial on pages 418-420)

Ali Sabahi, Katherine A. Marsh, **Harel Dahari**, Peter Corcoran, Jennifer M. Lamora, Xuemei Yu, Robert F. Garry, Susan L. Uprichard. The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. **Virology** (2010) Nov 10;407(1):110-9 [**I.F. 3.0**]

Marianna Halasi, Huiping Zhao, **Harel Dahari**, Uppoor G. Bhat, Erick B. Gonzalez, Aleksander V. Lyubimov, Debra A. Tonetti, Andrei L. Gartel. Thiazole antibiotics against breast cancer. **Cell Cycle** 2010; Mar; 9(6):1214-1217. [**I.F. 4.2**].

Neumann AU, Phillips S, Levine I, Ijaz S, **Dahari H**, Eren R, Dagan S, Naoumov NV. Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. **Hepatology** (2010); Sep;52(3):875-85 [**I. F. 12.0**]

Dahari H*, Sainz Jr*. B, Perelson AS, Uprichard SL. Modeling subgenomic HCV RNA kinetics during interferon- α treatment. **J Virology** (2009) Jul;83(13):6383-90. [**I. F. 5.1**] (* equal contributors)

Burg D, Libin R, Neumann AU, **Dahari H**. Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection. **Journal Theoretical Biology** (2009) Aug 21;259(4):751-9. [**I. F. 2.3**]

Dahari H, Shudo E, Cotler SJ, Layden TJ, Perelson AS. Modeling HCV kinetics: The relationship between the infected cell loss rate and the final slope of viral decay. **Antiviral Therapy** (2009) 14(3):459-64. [**I.F. 4.1**]

Dahari H, Layden-Almer JE, Kallwitz E, Ribeiro RM, Cotler SJ, Layden TJ, Perelson AS. A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. **Gastroenterology** (2009) Apr;136(4):1402-9. [**I. F. 12.6**]

Dahari H, Shudo E, Ribeiro RM, Perelson AS. Modeling complex decay profiles of hepatitis B virus during antiviral therapy. **Hepatology** (2009) Jan;49(1):32-38. [**I. F. 12.0**]

Reluga T, **Dahari H**, Perelson AS. Analysis of hepatitis C virus infection models with hepatocyte homeostasis. **SIAM Journal on Applied mathematics** (2009) 69(4): 999-1023 [**I. F. 1.5**]

Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of HCV RNA during antiviral therapy. **Hepatology** (2007) Jul;46(1):16-21. [**I. F. 12.0**] (Selected by Faculty of 1000 Biology: Factor 6.0 = Must Read)

Dahari H, Lo A, Ribeiro RM, Perelson AS. Modeling HCV Dynamics: Liver regeneration and critical drug efficacy. **Journal Theoretical Biology** (2007) Jul 21;247(2):371-81. [**I. F. 2.3**]

Dahari H, Markatou M, Zeremski M, Haller I, Ribeiro RM, Licholai T, Perelson AS, Talal AH. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated Interferon and ribavirin. **J Hepatology** (2007) July 47(1):23-30. [**I. F. 9.3**] (see Editorial July 47(1):1-3).

Dahari H, Ribeiro RM, Rice CM, Perelson AS. Mathematical modeling of subgenomic hepatitis C viral replication in Huh-7 cells. **J Virology** (2007) Jan;81(2):750-60. [**I. F. 5.1**]

Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, Feinstone SM, Neumann AU. Mathematical Modeling of Primary Hepatitis C Infection: Non-cytolytic clearance and early blockage of virion production. **Gastroenterology** (2005); 128(4): 1056-1066. [**I. F. 12.6**]

Dahari H, Feliu A, Garcia-Retortillo M, Fornis X, Neumann AU. Second Hepatitis C Compartment Indicated by Viral Dynamics during Liver Transplantation. **J Hepatology** (2005) April 42(4): 491-498. [**I. F. 9.3**] (see Editorial April 42(4):441-443).

Major ME, **Dahari H**, Mihalik K, Puig M, Rice CM, Neumann AU, Feinstone SM. Hepatitis C Virus Kinetics and Host Responses Associated with Disease and Outcome of Infection. **Hepatology** (2004) Jun;39(6):1709-20. [**I. F. 12.0**]

Pawlotsky JM, **Dahari H**, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L, Dhumeaux D. Antiviral Action of Ribavirin in Chronic Hepatitis C. **Gastroenterology** (2004) 126(3):703-14. [**I. F. 12.6**]

Bouvier-Alias M, Patel K, **Dahari H**, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM.. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. **Hepatology** (2002) 36(1): 211-218. [**I. F. 12.0**]

Neumann AU, Lam NP, **Dahari H**, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. **J Infectious Diseases**. (2000) July 182(1):28-35. [**I. F. 5.7**]

BOOK CHAPTERS AND REVIEWS

Guedj J, **Dahari H**, Uprichard SL, Perelson AS. The HCV NS5A inhibitor daclatasvir has dual mode of action and reveals a shorter HCV half-life estimate. **Expert Rev Gastroenterol Hepatol**. (2013) Jul;7(5):397-9.

Polyak SJ, Oberlies NH, Pécheur E, **Dahari H**, Ferenci P, Pawlotsky JM. Silymarin for HCV infection. **Antiviral Therapy** (2013) 18:141-147 [I.F. 4.1]

Dahari H, Guedj J, Perelson AS, Layden TJ. Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. **Current Hepatitis Reports** (2011) Volume 10, Number 3, 214-227.

Guedj J, Rong R, **Dahari H**, Perelson AS. A perspective on modeling hepatitis C virus infection. **J Viral Hepatitis** (2010); 17, 825–833.

Dahari H, Shudo E, Ribeiro RM, Perelson AS. Mathematical modeling of HCV infection and treatment. **Hepatitis C Protocols. 2nd ed. NJ: Humana Press** (2009): 439-453. Also published in **Methods Mol Biol**. 2009;510:439-53.

Dahari H, Layden-Almer JE, Perelson AS, Layden TJ. Hepatitis C viral kinetics in special populations. **Current Hepatitis Reports** (2008) Volume 7, Issue 3: 97-105.

LETTERS AND NOTES

Guedj J, Canini L, Cotler SJ, **Dahari H**. Reply: Effect of interferon-alfa therapy on hepatitis D virus. **Hepatology** (2014) in press [I. F. 12.0]

Dahari H & Cotler SJ. Individualized treatment for patients with low HCV load (genotype 1): A viral kinetic approach. **Hepatology** (2014) Jun;59(6):2422-3 [**I. F. 12.0**] NIHMSID #531892

Dahari H, Cotler SJ, Layden TJ, Perelson AS. Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling. **J Hepatology** (2013) vol. 58:831–843 [**I. F. 9.3**]; PubMed #23246507; NIHMSID #466174

Dahari H, Guedj J, Perelson AS. Silibinin's mode of action against HCV: A controversy yet to be resolved. **Hepatology** (2011) Aug;54(2):749. [I. F. 12.0]; PMC3677944

Guedj J, **Dahari H**, Perelson AS. Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy. **Proc Natl Acad Sci U S A.** (2011) Jul 19;108(29):E302. [I. F. 9.7]

Dahari H, Rong L, Layden TJ, Cotler SJ. Hepatocyte proliferation and hepatitis C virus (HCV) kinetics. **Clinical Pharmacology & Therapeutics** (2011) Mar;89(3):353-4. [I. F. 7.0]

Dahari H, Cotler SJ, Layden TJ, Perelson AS. Hepatitis B virus clearance rate estimates. **Hepatology** (2009) Apr 2;49(5):1779-1780. [I. F. 12.0]

Dahari H & Perelson AS. Hepatitis C virus RNA kinetics: Drug efficacy and the rate of HCV-infected cells loss. **World Journal Gastroenterology** (2007);13(21):3020-21. [I. F. 3.2]

Dahari H & Perelson AS. Hepatitis C virus kinetics in chimeric mice during antiviral therapy. **Hepatology** (2007) Oct 12;46(6):2048-2049. [I. F. 12.0]

Dahari H, Forns X, Neumann AU, Perelson AS. The extrahepatic contribution to HCV plasma viremia. **J Hepatology** (2006) Oct 45(4):626-7. [I. F. 9.3]

SUBMITTED MANUSCRIPTS

Gutfraind A, Boodram B, Prachand N, Hailegiorgis A, **Dahari H***, Major M*. Agent-based model forecasts aging of the population of people who inject drugs in metropolitan Chicago and changing prevalence of hepatitis C infections. (* equal contributors)

Echevarria D, Gutfraind A, Boodram B, Major M, Del Valle S, Cotler SJ, **Dahari H**. Modeling treatment scale up effect on hepatitis C prevalence among persons who inject drugs in metropolitan Chicago.

Katja Roos, Katharina Esser-Nobis, Paul Schnitzler, Swati DebRoy, **Harel Dahari**, Volker Lohmann, Christoph Eisenbach. Successful quadruple therapy with silibinin, telaprevir, ribavirin and pegIFN α 2a in a liver transplanted hepatitis c virus-infected patient.

PROFESSIONAL ACTIVITY

NIH Infectious Disease, Reproductive Health, and Asthma/Pulmonary Conditions (IRAP). Reviewer of IRAP study section held on Sep30 & Oct 1	9/2014
NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB). Reviewer of NIBIB study section held on 9/21/2012	9/2012
Steering Scientific Committee on Hepatitis C Diagnosis and Treatment: Ministry of Health of Brazil, Brasilia, DF, Brazil	9/2013

HONORS AND AWARDS

Areas of Excellence Award - UIC	2012
O1 Visa- Extraordinary Ability in Science	2009
Fulbright postdoctoral scholarship	2004/5
Scholarship for excellence - Dr. Michael Landau foundation	2000
President of Israel citation for excellence	1992

EDITORIAL BOARD	BMC Infectious Diseases (Associate editor)	2009 -
REFEREE IN SCIENTIFIC JOURNALS	<p>Liver Transplantation Computers and Mathematics with Applications Computers in Biology and Medicine Antiviral Therapy Journal of Bioinformatics and Computational Biology Statistics in Medicine Journal Hepatology Hepatology Gastroenterology Journal Infectious Diseases Journal of Virology Pharmacogenomics and Personalized Medicine Pharmacometrics & Systems Pharmacology Journal Theoretical Biology Journal Viral Hepatitis Mathematical Biosciences Mathematical Medicine and Biology PLoS Computational Biology BMC Infectious Diseases Journal of the Royal Society Interface Journal of the American Association of Pharmaceutical Scientists (AAPS journal) Expert Opinion On Biological Therapy American Journal of Transplantation</p>	
MEMBERSHIP	<p>European Association for the Study of the Liver (EASL) American Association for the Study of Liver Diseases (AASLD) The American Association for the Advancement of Science (AAAS) Society for Mathematical Biology (SMB) Society for Industrial and Applied Mathematics (SIAM) Computational Social Science Society of the Americans (CSSSA) American Society for Microbiology (ASM)</p>	
ORGANIZATION/ SCIENTIFC BOARD OF CONFERENCES	<p>Co-organizer: Mini-Symposia on modeling viral hepatitis dynamics: from bench to bedside. The 9th European Conference on Mathematical and Theoretical Biology, Gothenburg, Sweden</p> <p>Scientific Board: 2nd monothematic workshop on the antiviral mechanism of silibinin during HCV infection, Cologne, Germany</p> <p>Steering Scientific Committee on Hepatitis C Diagnosis and Treatment: Ministry of Health of Brazil, Brasilia, DF, Brazil</p> <p>Co-organizer: Mini-Symposia on modeling viral dynamics in-vivo and in-vitro during The Society for Mathematical Biology (SMB), Tempe, Arizona USA</p> <p>Scientific Board: monothematic workshop on the antiviral mechanism of silibinin during HCV infection, Cologne, Germany</p> <p>Organizer: Computational HCV epidemiology and vaccine trial design, Chicago, IL USA</p> <p>Co-Chairman and organizer: Mini-Symposiums on Modeling viral hepatitis dynamics in-vivo and in-vitro in the era of direct anti-viral agents I & II during European Society for Mathematical and Theoretical Biology, Krakow, Poland</p>	<p>6/2014</p> <p>5/2014</p> <p>9/2013</p> <p>6/2013</p> <p>2/2012</p> <p>10/2012</p> <p>7/2011</p>

INVITED PRESENTATIONS
AND SEMINARS

Liver Unit, Shaare Zedek Medical Center, Hebrew University, Jerusalem, Israel	1/2015
2 nd Latin American Symposia on Antiviral Therapy against HCV, Sao Paulo, Brazil	12/2014
11th JSH Single Topic Conference, Hiroshima, Japan	11/2014
Israel Association for the Study of the Liver: Annual meeting on treatment of viral hepatitis and HCC. Eilat, Israel	6/2014
2 nd Monothematic workshop on the antiviral mechanism of silibinin during HCV infection, Cologne, Germany	5/2014
The 1 st workshop on viral dynamics, Frankfurt, Germany	7/2013
q bio summer school – Santa Fe, NM, USA	7/2013
14th international Symposium on Viral Hepatitis and Liver Disease, Shanghai, China	2012
Monothematic workshop on the antiviral mechanism of silibinin during HCV infection, Cologne, Germany	2012
Digestive Disease Institute and at the Shaare Zedek Medical Center, Hebrew University, Jerusalem, Israel	2012
The 4th Annual Walter Payton Symposium: Management of hepatitis C, Chicago, IL, USA	2012
Early morning workshop on Mechanisms of Antiviral Therapy in Hepatitis C: the 62 nd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, USA	2011
The Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan Uni., Israel	2011
Felsenstein Medical Research Center, Tel Aviv Uni., Israel	2011
European Society for Mathematical and Theoretical Biology, Krakow, Poland	2011
HIV & Liver Diseases 2010 Conference, Jackson Hole, Wyoming, USA	2010
Meet-the-Professor Luncheon, the 61 st Annual Meeting of the American Association for the Study of Liver Diseases, Boston, USA	2010
1 st Latin American Symposia on Antiviral Therapy against HCV: STAT-C & Other New Therapy, Sao Paulo, Brazil	2010
SIAM Conference on Life Sciences, Pittsburgh, Pennsylvania	2010
Center for Nonlinear Studies, Los Alamos National Laboratory, NM, USA	2009
Institute of Biostatistics and Mathematical Modeling, Faculty of Medicine, Johann Wolfgang Goethe-University, Frankfurt, Germany	2008
Shanghai Institutes for Biological Sciences, Shanghai, China	2007
Department of Medicine, University of Illinois at Chicago, IL, USA	2007
Center for the Study of Hepatitis C, Rockefeller University- NY, USA	2005,2007
Faculty of Health Sciences, Ben Gurion University, Israel	2005
Laboratory for Biological Modeling, NIDDK, NIH, Bethesda, MD, USA	2005
Models and methods in Immunology- Eilat, Israel	2004
INSERM, La Roche-Posay, France	2002

MEETING
PROCEEDINGS

1. Laetitia Canini, Christopher Koh, Scott J. Xiongce Zhao, Susan L. Uprichard, Vanessa Haynes-Williams, Mark A. Winters, Gitanjali Subramanya, Stewart Cooper, Peter Pinto, Erin Wolff, Rachel Bishop, Ma Ai Thanda Han, David E. Kleiner, Onur Keskin, Ramazan Idilman, Cihan Yurdaydin, Jeffrey S. Glenn, Theo Heller and **Harel Dahari**. Understanding hepatitis delta virus and HBsAg kinetics during treatment with prenylation inhibitor lonafarnib via mathematical modeling. 50th annual meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria: April 22 –26, 2015; **J Hepatology** 2015; LP36 (**Late Breaker ePoster**)
2. Christopher Koh, Laetitia Canini, **Harel Dahari**, David Cory, Mark A. Winters, Matthew Bys, Ingrid Choong, Jeffrey S. Glenn, Theo Heller. Oral Prenylation Inhibition with Lonafarnib in Chronic Hepatitis D Infection: A Randomized, Double-Blinded, Placebo-Controlled Proof-of-Concept Study. CROI 2015, Seattle, Washington, Feb 23-26, 2015.
3. Laetitia Canini, Christopher Koh, Scott J. Cotler, David Cory, Mark A. Winters, Matthew Bys, Ingrid Choong, Jeffrey S. Glenn, Theo Heller and **Harel Dahari**. Understanding hepatitis delta virus dynamics and antiviral efficacy of the prenylation inhibitor lonafarnib. 65th Annual Meeting of the American Association for the study of Liver Diseases. Boston MS, USA: Nov 7 –11, 2014; **Hepatology** 2014; 60:4(Suppl): 317A (**oral presentation**)
4. Christopher Koh, Cihan Yurdaydin, David Cory, **Harel Dahari**, Vanessa Haynes-Williams, Mark A. Winters, Matthew Bys, Ingrid Choong, Laetitia Canini, Peter Pinto, Erin F. Wolff, Rachel J. Bishop, Stewart Cooper, David E Kleiner, T. Jake Liang, Jay H. Hoofnagle, Jeffrey S. Glenn and Theo Heller. Prenylation Inhibition with Lonafarnib decreases hepatitis D levels in humans. 65th Annual Meeting of the American Association for the study of Liver Diseases. Boston MS, USA: Nov 7 –11, 2014; **Hepatology** 2014; 60:4 (Suppl): 1092A-1093A.
5. Yuji Ishida, Tje Lin Chung, Michio Imamura, Nobuhiko Hiraga, Laetitia Canini, Susan Uprichard, Alan S. Perelson, Chise Tateno, **Harel Dahari**, Kazuaki Chayama. HBV infection in humanized chimeric mice has multiphasic viral kinetics from inoculation to steady state and an HBV half-life of 1 hr. 65th Annual Meeting of the American Association for the study of Liver Diseases. Boston MS, USA: Nov 7 –11, 2014; **Hepatology** 2014; 60:4(Suppl): 1023A-1024A.
6. Natasha Sansone, **Harel Dahari**, Gitanjali Subramanya, Alan S. Perelson, and Susan L. Modeling HCVcc infection reveals new insights into the dynamics that maintain the in vitro HCV steady state and the mechanisms of action of the NS5A inhibitor daclatasvir. 65th Annual Meeting of the American Association for the study of Liver Diseases. Boston MS, USA: Nov 7 –11, 2014; **Hepatology** 2014; 60:4 (Suppl): 1165A.
7. Swati DebRoy, Nobuhiko Hiraga, Michio Imamura, Laetitia Canini, Ralf T. Pohl, Stefano Persiani, Susan Uprichard, Alan S. Perelson, Chise Tateno, Kazuaki Chayama, **Harel Dahari**. HCV kinetics in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy. 65th Annual Meeting of the American Association for the study of Liver Diseases. Boston MS, USA: Nov 7 –11, 2014; **Hepatology** 2014; 60:4(Suppl): 1171A-1172A.
8. Desarae Echevarria, Alexander Gutfraind, Basmattee Boodram, Marian Major, Scott J Cotler, **Harel Dahari**. Modeling treatment scale up effect on hepatitis C prevalence among persons who inject drugs in metropolitan Chicago. 65th Annual Meeting of the American Association for the study of Liver Diseases. Boston MS, USA: Nov 7 –11, 2014; **Hepatology** 2014; 60:4(Suppl): 671A-672A.
9. **Harel Dahari**, Shimon Shteingart, Inna Gafanovich, Scott J. Cotler, Massimo D’Amato, Ralf T. Pohl, Gali Weiss, Yaakov J. Ashkenazi, Thomas Tichler, Eran Goldin, Yoav Lurie. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modeling of HCV kinetics. 21st International Symposium on HCV and related Viruses. Banff, Canada, Sep 7-11, 2014.
10. Natasha Sansone, **Harel Dahari**, Gitanjali Subramanya, Alan S. Perelson, and Susan L. Uprichard. Modeling HCVcc infection reveals new insights into the dynamics that maintain in vitro HCV steady state and the mechanisms of action of the NS5A inhibitor daclatasvir. 21st International Symposium on HCV and related Viruses. Banff, Canada, Sep 7-11, 2014.
11. Canini L, DebRoy S, Mariño Z, Crespo G, Navasa M, D’Amato M, Ferenci P, Cotler SJ, Forns X, Perelson AS, **Dahari H**. Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. 2nd monothematic workshop on the antiviral mechanism of silibinin during HCV infection, Cologne, Germany. May 2014 (**Oral presentation**)
12. **Harel Dahari**, Shimon Shteingart, Inna Gafanovich, Scott J. Cotler, Massimo D’Amato, Ralf T. Pohl, Gali Weiss, Yaakov J. Ashkenazi, Thomas Tichler, Eran Goldin, Yoav Lurie. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modeling of HCV kinetics. Israel Association for the Study of the Liver. Eilat, Israel; June 2014 (**Oral presentation**)
13. **Harel Dahari**, Shimon Shteingart, Inna Gafanovich, Scott J. Cotler, Massimo D’Amato, Ralf T. Pohl, Gali Weiss, Yaakov J. Ashkenazi, Thomas Tichler, Eran Goldin, Yoav Lurie. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modeling of HCV kinetics. 1st world conference on Targeting Liver Diseases World Congress. Jerusalem, Israel June 2014
14. Canini L, DebRoy S, Mariño Z, Crespo G, Navasa M, D’Amato M, Ferenci P, Cotler SJ, Forns X, Perelson AS, **Dahari H**. Hepatitis C virus kinetic comparison between compensated liver disease patients and patients awaiting liver transplantation treated with intravenous silibinin monotherapy. 64th Annual Meeting of the American Association for the study of Liver Diseases. Washington DC,; Nov 1 –5, 2013; **Hepatology** 2013;(Suppl)58 volume 4:758A .
15. Chung TL, Ishida Y, Chayama K, Imamura M, Hiraga N, Uprichard SL, Perelson AS, **Dahari H**. Multiscale mathematical modeling of HBV kinetics in humanized chimeric mice during treatment with lamivudine and/or pegylated interferon- α -2a. 64th Annual Meeting of the American Association for the study of Liver Diseases. Washington DC,; Nov 1 –5, 2013; **Hepatology** 2013;(Suppl)58 volume 4:655A.
16. Guedj J, Rotman Y, Cotler SJ, Schmid P, Albrecht J, Haynes-Williams V, Liang T.J, Hoofnagle J.H, Heller T, **Dahari H**. Understanding early hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha

- therapy via mathematical modeling. 64th Annual Meeting of the American Association for the study of Liver Diseases. Washington DC.: Nov 1 –5, 2013; **Hepatology** 2013;(Suppl)58 volume 4:688A .
17. Alexander Gutfraind, Basmattee Boodram, Lawrence J. Ouellet, Nikhil Prachand, Stephen Feinstone, Susan M Mniszewski, Richard Novak, Alan S. Perelson, Sara del Valle, **Harel Dahari**, Marian Major. Integrating rich survey datasets in computational simulations of hepatitis C virus infection among injecting drug users in Chicago area. 10th International Conference on Health Policy Statistics; Chicago, IL, USA, Oct 9-11, 2013
 18. Gutfraind A, Boodram B, Ouellet LJ, Prachand N, Perelson AS, Feinstone S, Novak RM, Mniszewski SM, Del Valle SY, **Dahari H**, Major M. Implementing a data-driven model of hepatitis C infections in metropolitan Chicago: a concept paper. Proceedings of the 8th INFORMS Workshop on Data Mining and Health Informatics; (2013) In: Seref O, Serban N, Zeng D (eds).
 19. Tje Lin Chung, Gonzalo Crespo, Laura Mensa, Sofia Perez-del-Pulgar, Miquel Navasa, Alan S. Perelson, Scott J Cotler, Susan L. Uprichard, Xavier Forns, **Harel Dahari**. Detailed viral kinetics during liver transplantation (LT) indicates that the liver plays a role in HCV clearance. 20th International Symposium on HCV and related Viruses. (**Oral presentation**) Melbourne, Australia Oct 7-10, 2013
 20. Frederik Graw, Danyelle N. Martin, Alan S. Perelson, Susan L. Uprichard, **Harel Dahari**. Quantification of HCV cell-to-cell spread using a stochastic modeling approach. 20th International Symposium on HCV and related Viruses. Melbourne, Australia Oct 7-10, 2013
 21. Natasha Sansone, **Harel Dahari**, Gitanjali Subramanya, Alan S. Perelson, Susan L. Uprichard. Characterization of intracellular and extracellular of HCV inhibition kinetics during in vitro treatment with DAAs. 20th International Symposium on HCV and related Viruses. Melbourne, Australia Oct 7-10, 2013
 22. Tje Lin Chung, Gonzalo Crespo, Laura Mensa, Sofia Perez-del-Pulgar, Miquel Navasa, Scott J Cotler, Xavier Forns, **Harel Dahari**. HCV kinetics during and after the anhepatic phase: Is the liver the primary site for HCV clearance? 48th annual meeting of the European Association for the Study of the Liver (EASL). **J Hepatol** 2013;58(Suppl 1): S229-230
 23. Swati DebRoy, Zoe Mariño, Gonzalo Crespo, Miquel Navasa, Massimo D'Amato, Scott J Cotler, Xavier Forns, **Harel Dahari**. Modeling HCV kinetics during intravenous silibinin monotherapy in peri-transplant period. 48th annual meeting of the European Association for the Study of the Liver (EASL); **J Hepatol** 2013;58(Suppl 1): S330-331
 24. **Harel Dahari**, Maria Rendina, Alfonso Ramunni, Scott J. Cotler, Alan S. Perelson, Nicola M Castellaneta, Antonino Castellaneta, Marianna Zappimulso, Roberto Bringiotti, Salvatore F Rizzi, Annamaria Squicciarino, Antonio Francavilla and Alfredo Di Leo. Impact of double filtration plasmapheresis in combination with PEG-IFN and ribavirin in previous non responders: a longitudinal HCV kinetic analysis. 63rd Annual Meeting of the American Association for the study of Liver Diseases. San Francisco, CA: Nov 9 –13, 2012; **Hepatology** 2012;(Suppl)56 volume 4:718 .
 25. **Harel Dahari***, Jeremie Guedj*, Libin Rong*, Patrick Smith, Alan S. Perelson. Multiscale modeling approach predicts that the protease inhibitor danoprevir blocks several distinct stages of the HCV replication in vivo. 19th International Symposium on HCV and related Viruses. Venice, Italy, Oct 5-9, 2012
 26. Guedj J, Rotman Y, Schmid P, Albrecht J, Haynes-Williams V, Liang T.J, Hoofnagle J.H, Heller T, **Dahari H**. Modeling HDV and HBsAg kinetics during pegylated interferon-alfa treatment. 47th annual meeting of the European Association for the Study of the Liver (EASL). **J Hepatol** 2012;56(Suppl 2):S200
 27. Zhang J, Lipton H, Perelson AS, **Dahari H**. Modeling Theiler murine encephalomyelitis virus (TMEV) infection in mice. Systems Approaches in Immunology. Santa Fe, NM, USA Jan 6-7, 2012
 28. Guedj J[#], **Dahari H*** Rong L, Nettles RE, Cotler SJ, Layden JE, Perelson AS. Systems Approaches in Immunology. Santa Fe, NM, USA Jan 6-7, 2012 (**#oral presentation**)
 29. Malespin MH, Kemerly EK, Luc BJ, Mettu PS, Thomas JL, Wong SS, Cotler SJ, **Dahari H**. Longitudinal analysis of HBV replication and ALT levels in an urban Chinatown community. College of Medicine - Research Forum, Chicago, IL, USA, Nov 1, 2011
 30. Sansone N, Barretto N, Guedj J, Perelson AS, Uprichard SL*, **Dahari H***. Modeling inhibition kinetics of HCV sg1b RNA during IFN/DAAs treatment in non-growing Huh7 cells. College of Medicine - Research Forum, Chicago, IL, USA, Nov 1, 2011
 31. Perelson AS[#], Guedj J, **Dahari H**. HCV viral kinetics in the age of DAAs. HEPDART 2011 frontiers in drug development for viral hepatitis. Koloa, Hawaii, Dec 4-8, 2011 (**#oral presentation**)
 32. **Dahari H***, Guedj J* Pohl RT, Ferenci P, Perelson AS Understanding silibinin's modes of action against HCV using viral kinetic modeling. 62nd Annual Meeting of the American Association for the study of Liver Diseases. San Francisco, CA: Nov 4 –8, 2011; **Hepatology** 2011; 54(Suppl): 802A
 33. Guedj J, **Dahari H**, Shudo E, Smith P, Perelson AS[#]. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). 62nd Annual Meeting of the American Association for the study of Liver Diseases. San Francisco, CA: Nov 4 –8, 2011; **Hepatology** 2011; 54(Suppl): 85A (**#oral presentation**)
 34. **Dahari H**, Barretto N, Sansone N, Guedj J, Perelson AS, Uprichard SL. Modeling inhibition kinetics of HCV sg1b RNA during IFN/DAAs treatment in non-growing Huh7 cells. 62nd Annual Meeting of the American Association for the study of Liver Diseases. San Francisco, CA: Nov 4 –8, 2011; **Hepatology** 2011; 54(Suppl): 538A
 35. Guedj J[#], **Dahari H***, Rong L, Nettles RE, Cotler SJ, Layden JE, Perelson AS. New insights into the mechanisms of action of interferon-alpha and BMS-790052: a multi-scale mathematical modeling approach. 18th International Symposium on HCV and related Viruses. Seattle, WA, USA Sep 8-12, 2011 (**#oral presentation**)
 36. **Dahari H**, Barretto N, Sansone N, Guedj J, Perelson AS, Uprichard SL. Modeling inhibition kinetics of HCV sg1b RNA during IFN/DAAs treatment in non-growing Huh7 cells. 18th International Symposium on HCV and related Viruses. Seattle, WA, USA Sep 8-12, 2011

37. Guedj J, **Dahari H**, Shudo E, Smith P, Perelson AS. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). 18th International Symposium on HCV and related Viruses. Seattle, WA, USA Sep 8-12, 2011
38. **Dahari H**, Guedj J, Rong L, Nettles RE, Cotler SJ, Layden JE, Perelson AS. New insights into the mechanisms of action of interferon-alpha and BMS-790052: a multi-scale mathematical modeling approach. 46th annual meeting of the European Association for the Study of the Liver (EASL). **J Hepatol** 2011;54(Suppl):S474.
39. **Dahari H**, Barretto N, Sainz B, Jr., Guedj J, Perelson AS, Uprichard SL. Modeling interferon-alpha mediated inhibition kinetics of intracellular and extracellular HCV RNA during HCV infection in vitro. 46th annual meeting of the European Association for the Study of the Liver (EASL). **J Hepatol** 2011;54(Suppl):S312.
40. **Dahari H**, Guedj J, Cotler SJ, Nettles R.E, Layden T.J, Perelson, A.S: Higher hepatitis C virus (HCV) clearance rates during treatment with direct acting agents compared to interferon-alpha. 61st Annual Meeting of the American Association for the study of Liver Diseases. Boston, MA: Oct 29 –Nov 2, 2010; **Hepatology** 2010, 52(Suppl)718A-719A.
41. **Dahari H**, Araújo ES, Cotler SJ, Thomas J. Layden, Avidan U. Neumann , Carlos E. Melo, Fernando F. Tatsch, Antônio Alci Barone: Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients. 61st Annual Meeting of the American Association for the study of Liver Diseases. Boston, MA: Oct 29 –Nov 2, 2010; **Hepatology** 2010, 52(Suppl) (**Selected poster**)
42. **Dahari H**, Sainz B,M, Barretto N, Perelson AS, Uprichard SL. Modeling interferon-alpha mediated inhibition kinetics of intracellular and extracellular HCV RNA during HCV infection in vitro. 17th International Symposium on HCV and related Viruses. Yokohama, Japan, Oct 10-14 2010.
43. **Dahari H**, Fienstone S, Major M. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. 17th International Symposium on HCV and related Viruses. Yokohama, Japan, Oct 10-14 2010.
44. Araújo ES, **Dahari H**, Cotler SJ, Thomas J. Layden, Avidan U. Neumann, Carlos E. Melo, Fernando F. Tatsch, Antônio Alci Barone: Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients. 17th International Symposium on HCV and related Viruses. Yokohama, Japan, Oct 10-14 2010.
45. L. Rong, **H. Dahari**, R.M. Ribeiro, A.S. Perelson. Rapid emergence of hepatitis C virus protease inhibitor resistance. 3rd Biennial IDEa Symposium. June 16 - 18, 2010, Bethesda, MD
46. **Dahari H**, Evaldo S. Affonso de Araujo, Bart L. Haagmans, Thomas J. Layden, Scott J. Cotler, Antonio A. Barone, Avidan U. Neumann. Early viral kinetic and pharmacodynamic predictions of response to treatment with PEG-IFN-2a in HIV/HCV co-infected patients. 15th International Symposium on HCV and related Viruses. Nice, France, Oct 2009.
47. **Dahari H**, Sainz B, Marsh K, Uprichard SL, Perelson AS. A novel approach to understanding the mode of action of interferon-alpha mediated inhibition of subgenomic HCV replication. 15th International Symposium on HCV and related Viruses. San Antonio, Texas, Oct 2008.
48. **Dahari H**, Sainz B,M, Perelson AS, Uprichard SL. Subgenomic HCV RNA decline during interferon- α treatment is biphasic and dose dependent. 15th International Symposium on HCV and related Viruses. San Antonio, Texas, Oct 2008.
49. Sabahi A, Sainz B, LaMora J, **Dahari H**, Garry R, Uprichard SL. Kinetics of productive HCV infection in vitro. 15th International Symposium on HCV and related Viruses. San Antonio, Texas, Oct 2008.
50. **Dahari H**, Layden-Almer JE ,Perelson AS, Layden TJ. Modeling complex decay profiles of hepatitis B virus during antiviral therapy. EASL-AASLD-APASL-ALEH-IASL Conference Hepatitis B & C Virus Resistance to Antiviral Therapies, Paris, France, February, 14-16, 2008.
51. **Dahari H**, Layden-Almer JE, Kallwitz E, Ribeiro RM, Cotler SJ, Layden TJ, Perelson AS. Modeling hepatitis C virus dynamics: Why patients with high baseline viral load or with advanced liver disease are difficult to treat. EASL-AASLD-APASL-ALEH-IASL Conference Hepatitis B & C Virus Resistance to Antiviral Therapies, Paris, France, February, 14-16, 2008.
52. **Dahari H**; Ribeiro, RM; Perelson, AS. Modeling HCV dynamics During Antiviral Therapy: Triphasic viral decline, flat partial response and critical drug efficacy. Hepatitis Single Topic Conference (AASLD). 14th International Symposium on HCV and related Viruses. Sep. 2007
53. Churkin A, **Dahari H**, Kuiken C, Perelson AS, Uprichard S, Barash D. Computational Investigations into the Mechanism by which there is an Asymmetry between the Synthesis of Plus and Minus HCV RNAs. 14th International Symposium on HCV and related Viruses. Sep. 2007
54. **Dahari H**; Ribeiro, RM; Perelson, AS. Triphasic viral decline, flat partial response and critical drug efficacy. Hepatitis Single Topic Conference (AASLD). March 2007.
55. **Dahari H**; Ribeiro, RM; Rice, CM; Perelson, AS. Mathematical modeling of subgenomic hepatitis C viral replication in Huh-7 cells. *J Hepatology*; 2006; v.44, suppl.2, p.S273-S273.
56. **Dahari H**, Ribeiro RM, Perelson AS. Modeling hepatitis C viral replication in cell culture. ECMTB; July 2005, book of abstracts 1, p.313.
57. **Dahari H**; Ribeiro, RM; Perelson, AS. Mathematical modeling of intracellular subgenomic HCV RNA kinetics during treatment in HUH-7 cells. *Hepatology*; OCT 2005; v.42, no.4, Suppl. 1, p.564A
58. **Dahari H**; Ribeiro, RM; Zeremski, M; Licholai, T; Haller, I; Perelson, AS; Talai, AH. Modeling ribavirin pharmacokinetics in HIV-1/HCV-coinfected patients predicts higher intracellular ribavirin concentration in sustained viral responders. *Hepatology*; OCT 2005; v.42, no.4, Suppl. 1, p.669A-670A.

59. **Dahari H**, Ribeiro RM, Perelson AS. Modeling hepatitis C viral replication in cell culture. ECMTB; July 2005, book of abstracts 1, p.313.
60. **Dahari H**, Ribeiro RM, Perelson AS. Mathematical modeling of subgenomic hepatitis C viral replication in Huh-7 cells. Submitted to 12th International Symposium on Hepatitis C Virus and Related Viruses. October 2-6, 2005 in Montréal (Québec, Canada).
61. **Dahari H**, Ribeiro RM, Perelson AS. Mathematical modeling of intracellular subgenomic HCV RNA kinetics during antiviral treatment in Huh-7 cells. 56th Annual Meeting of the American Association for the study of Liver Diseases. San Francisco, CA: November 11-15, 2005.
62. **Dahari H**; Homburger, Y; Verheij-Hart, E; von Wagner, M; Goulis, I; Lurie, Y; Missale, G; Vrolijk, JM; Esteban, JI; Hezode, C; et. al. Effects of PEG-IFN-alpha 2a (40KD) dose reduction, ribavirin dose reduction and ribavirin interruption on hepatitis C viral kinetics and its correlation to SVR in the DITTO-HCV study. HEPATOLOGY; OCT 2004; v.40, no.4, suppl.1, p.324A-324A
63. Neumann, A. U., Lam, N. P., **Dahari, H.**, Gretch, D. R., Wiley, T. E., Layden, T. J., and Perelson, A. S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Dynamic Formal Modelling in Physiopathology and Therapeutic Research (INSREM). 2-7-2002. 2-7-2002.
64. Neumann, A. U., Lam, N. P., **Dahari, H.**, Gretch, D. R., Wiley, T. E., Layden, T. J., and Perelson, A. S. Full Mathematical Characterization of the Dynamical Parameters of Acute Hepatitis C Viral Infection in Chimpanzees . Mahemathical Modelling & Computing in Biology and Medicine (ESTMB 5th conference). 7-3-2002.
65. **Dahari H**, Garcia-Retortillo, M., Forns, X., and Neumann AU. SECOND HEPATITIS C COMPARTMENT INDICATED BY VIRAL DYNAMICS DURING LIVER TRANSPLANTATION. (9th International Meeting on HCV and Related Viruses). 7-7-2002. 7-7-2002.
66. **Dahari H**, Garcia-Retortillo, M., Forns, X., and Neumann AU. SECOND HEPATITIS C COMPARTMENT INDICATED BY VIRAL DYNAMICS DURING LIVER TRANSPLANTATION. (Therapies for Viral Hepatitis). 29-10-2002.
67. **Dahari H**, Garcia-Retortillo, M., Forns, X., and Neumann AU. SECOND HEPATITIS C COMPARTMENT INDICATED BY VIRAL DYNAMICS DURING LIVER TRANSPLANTATION. Hepatology (53rd Annual Meeting of the AASLD). 5-11-2002.
68. **Dahari H**, Major, M. E., Mihalik, K., Feinstone, S. M., Perelson AS, and Neumann AU. A "Three Punch" Immune Response is Required for Spontaneous Clearance of Primary HCV Infection. 8th International Symposium on HCV and related Viruses. 9-3-2001.
69. **Dahari H.**, Bouvier-Alias, M., Patel, K., Beaucourt, S., Larderie, P., Blatt, L., Hezode, C., Picchio, G., Dhumeaux, D., Neumann, A. U., McHutchison, J. G., and Pawlotsky, J. M. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. 8th International Symposium on HCV and related Viruses. 9-3-2001
70. **Dahari H**, Major, M. E., Mihalik, K., Feinstone, S. M., Perelson AS, and Neumann AU. Modeling Primary HCV Infection in Chimpanzees. 8th HIV Dynamics and Evolution Meeting. 29-4-2001. 8-3-2000.
71. **Dahari H**, Major, M. E., Mihalik, K., Feinstone, S. M., and Neumann AU. Virus Cytopathicity and IFN and Specific Immune Responses during Primary Infection. International Meeting on Mathematics in Biology. 2-9-2001. 8-3-2000.
72. Neumann AU, Lam NP, Davidian M, **Dahari H**, et al. Differences in hepatitis C virus (HCV) dynamics between HCV of genotype 1 and genotype 2. Hepatology 1999; 30: (4) 121.
73. Neumann, A. U., **Dahari, H.**, Conrad, A., Pianko, S., and McHutchinson, J. G. Early prediction and mechanism of the Ribavirin/IFN-alpha dual therapy effect on chronic hepatitis C virus (HCV) infection. Hepatology 1999; 30: (4) 595.
74. Lam NP, Neumann AU, **Dahari H**, Mihalov M, Wiley TE, Layden TJ. Second phase decline of HCV genotype 1 is slower in prior interferon (IFN) nonresponders (NR) than IFN naive patients. Hepatology 1998; 28: (4) 837.
75. Lam NP, Neumann AU, **Dahari H**, et al. Early viral decline slopes during daily high dose interferon (IFN) are predictive markers of subsequent virologic response. Hepatology 1998; 28: (4) 940.
76. Neumann AU, **Dahari H**, Lam NP, Wiley TE, Layden TJ. Basic reproduction factor of hepatitis C virus (HCV) and its implications to pathogenesis and therapy. Hepatology 1998; 28: (4) 1639.
77. Pawlotsky JM, **Dahari H**, Conrad A, et al. effect of intermittent interferon (IFN), daily IFN and IFN plus ribavirin induction therapy on hepatitis C virus (HCV) genotype 1b replication kinetics and clearance. Hepatology 1998; 28: (4) 502 .

(* equal contributors)